Literature DB >> 10546083

[Vulnerability to schizophrenia. II: Familial status of auditory evoked potential abnormalities].

T d'Amato1, B Karoumi, F Rosenfeld, M Saoud, A M Brunon, J Dalery.   

Abstract

The existence of a genetic background is well admitted in schizophrenia, but some individuals at genetic risk for that disease could never manifest it at a clinical level. However, several vulnerability models could help us to identify such individuals. According to them, when similar perturbations at a given task are observed both in clinically stable patients with schizophrenia and their nonschizophrenic first degree relatives, this task could be qualify as an indicator of the vulnerability to schizophrenia. In literature, that seems the case for auditory ERP late components in oddball paradigms. Our study was undertaken to replicate literature data. For that purpose, amplitude and latencies of auditory N100, P200, N200 and P300 wave-forms were assessed among 21 clinically, stable schizophrenics, 21 of their biological full siblings and 21 unrelated control subjects matched with the two others groups for several socio-demographic factors. Comparison were performed by non parametric analyses (Kruskal-Wallis one way ANOVA, and post-hoc Mann-Whitney). Compared to controls, delayed latencies and/or reduced amplitudes were observed for several ERP components--mainly with P300--in the sibling group. ERP values from this group did not statistically differ from those of the group with schizophrenia. In conclusion, results from the sibling group suggest that ERP impairments in auditory oddball paradigms may actually represent indicators of the genetic vulnerability to schizophrenia.

Entities:  

Mesh:

Year:  1999        PMID: 10546083

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  1 in total

1.  The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components.

Authors:  Patrick M Connolly; Christina Maxwell; Yuling Liang; Jonathan B Kahn; Stephen J Kanes; Ted Abel; Raquel E Gur; Bruce I Turetsky; Steven J Siegel
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.